We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Altimmune Inc
27 own
6 watching
Current Price
$4.04
$0.04
(1%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
198.77M
52-Week High
23.49
52-Week Low
3.82
Average Volume
2.17M
Dividend Yield
--
P/E Ratio
--
Market Capitalization198.77M52-Week High23.4952-Week Low3.82Average Volume2.17MDividend Yield--P/E Ratio--What does the Altimmune Inc do?
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More
How much money does Altimmune Inc make?
News & Events about Altimmune Inc.
PR Newswire
1month ago
Thinking about buying stock in Advanced Micro Devices, BigBear.ai, Riot Platforms, Bit Digital, or Altimmune? Thinking about buying stock in Advanced Micro Devices, BigBear.ai, Riot Platforms, Bit Digital, or Altimmune? PR Newswire NEW YORK, April 18, 2023 NEW YORK, April 18, 2023 /PRNewswire...
PR Newswire
1month ago
Thinking about buying stock in AMC Entertainment, Li Auto, Kingsoft Cloud, Altimmune, or Ford Motor? Thinking about buying stock in AMC Entertainment, Li Auto, Kingsoft Cloud, Altimmune, or Ford Motor? PR Newswire NEW YORK, April 17, 2023 NEW YORK, April 17, 2023 /PRNewswire...
Ticker Report
2 months ago
Altimmune (NASDAQ:ALT Get Rating)s stock had its market outperform rating restated by equities research analysts at JMP Securities in a research report issued on Wednesday, Benzinga reports. They currently have a $26.00 price objective on the stock. A number of other ...
Globe Newswire
4 months ago
Mr. Jordt brings over 25 years of industry experience in corporate strategy and business developmentGAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business ...
Globe Newswire
4 months ago
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the ...
Frequently Asked Questions
Frequently Asked Questions
What is Altimmune Inc share price today?
Can Indians buy Altimmune Inc shares?
How can I buy Altimmune Inc shares from India?
Can Fractional shares of Altimmune Inc be purchased?
What are the documents required to start investing in Altimmune Inc stocks?
What is today’s traded volume of Altimmune Inc?
What is today’s market capitalisation of Altimmune Inc?
What is the 52-Week High and Low Range of Altimmune Inc?
What percentage is Altimmune Inc down from its 52-Week High?
What percentage is Altimmune Inc up from its 52-Week Low?
Current Price
$4.04
$0.04
(1%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.